Penumbra Inc

PEN: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
^>%LOCK|zZLOCK|!Vb#?!

Penumbra Earnings: Recent Trial Data Offer Bright Prospects for Strong Growth

Penumbra delivered third-quarter results that featured revenue and net income growth of 17% (in constant currency) and 35%, respectively. The firm recently shared favorable data from its landmark study on computer assisted vacuum thrombectomy, or CAVT, for pulmonary embolism.

Sponsor Center